Figure 4
Validation of the instrument in different partitions of the dataset. Linear regression plot of the developed device verses TSB on 230 neonates, when (a) 90% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (d) 95% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (g) 98% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. Linear regression plot of the developed device verses Hb on 1073 neonates, when (b) 90% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (e) 95% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (h) 98% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. Linear regression plot of the developed device verses SpO2 on 340 neonates, when (c) 90% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (f) 95% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot. (i) 98% of the acquired data points are scattered within ± 0.02% from the cumulative fitted curve in the residual plot.
